Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403152 | 0.77 | ALDH1A1 (0.42) | SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL14385914 | 0.70 | KMT2A (0.51) | NPC1RAB9ASMN1; SMN2GAAKMT2A | |
| SCHEMBL885089 | 0.68 | BCAT2 (0.68) | BCAT2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL50338 | 0.68 | BCAT2 (0.68) | BCAT2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL885090 | 0.68 | BCAT2 (0.68) | BCAT2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL13234198 | 0.68 | KDM4E (0.34) | SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL1520684 | 0.68 | BCAT2 (0.72) | BCAT2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL26906281 | 0.68 | BCAT2 (0.72) | BCAT2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL13403149 | 0.67 | KDM4E (0.36) | KMT2AKDM4E | |
| Acetic Acid SCHEMBL8330086 | 0.67 | BCAT2 (0.66) | BCAT2NPC1RAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | PRKAR2B, GRK3, PRKAR2A | BCAT2 3177/4885NPC1 2467/4885RAB9A 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.